KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Assets (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Assets for 15 consecutive years, with $605.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 1.86% year-over-year to $605.2 million, compared with a TTM value of $605.2 million through Dec 2025, up 1.86%, and an annual FY2025 reading of $605.2 million, up 1.86% over the prior year.
  • Assets was $605.2 million for Q4 2025 at Travere Therapeutics, up from $538.6 million in the prior quarter.
  • Across five years, Assets topped out at $828.4 million in Q1 2022 and bottomed at $504.4 million in Q3 2024.
  • Average Assets over 5 years is $682.3 million, with a median of $726.2 million recorded in 2022.
  • The sharpest move saw Assets surged 33.33% in 2021, then dropped 25.16% in 2024.
  • Year by year, Assets stood at $776.6 million in 2021, then fell by 13.4% to $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then decreased by 24.69% to $594.1 million in 2024, then grew by 1.86% to $605.2 million in 2025.
  • Business Quant data shows Assets for TVTX at $605.2 million in Q4 2025, $538.6 million in Q3 2025, and $555.3 million in Q2 2025.